Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin added to sitagliptin with or without metformin in type 2 diabetes
2009-012806-37Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin add-on with Placebo add-on (2 arms). Primary endpoint: Change in haemoglobin A1c from baseline to week 24. Started Jul 2009; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-012806-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012806-37.